LGALS1 and metabolic disease: Going forward, advancing the knowledge around galectin-1 in obesity and metabolic disease could further shed light on the pathophysiology of T2D and its complications and help to find out whether galectin-1 has potential as a biomarker in prediabetes and T2D.